Who are Eledon Pharmaceuticals, Inc.'s main suppliers?

Eledon Pharmaceuticals, Inc. (ELDN) key suppliers include: THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC, THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE, ORANY, ORANY, Sanofi and 1 more. View the full supplier network at chainsifter.com/chain/ELDN.

Who are Eledon Pharmaceuticals, Inc.'s major customers?

Eledon Pharmaceuticals, Inc. (ELDN) key customers include: COASTLANDS-CAPITAL-PARTNERS-LP, ORANY, ORANY, Sanofi, Sanofi. View the full customer network at chainsifter.com/chain/ELDN.

What sector is Eledon Pharmaceuticals, Inc. in?

Eledon Pharmaceuticals, Inc. (ELDN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ELDN Supply Chain: Eledon Pharmaceuticals, Inc. Supplier List & 14 Relationships

6Suppliers

5Customers

3Debt Items

20Related Chains

Eledon Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC	THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC	90%	we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Foundation, Inc.
THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE	THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE	90%	In May 2015, Anelixis executed a License Agreement (the “Agreement”), which is an exclusive patent rights agreement with ALS Therapy Development Institute (“ALS TDI”) for certain patents and “know-ho…
ORANY	ORANY	72%	ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced …
SNYNF	Sanofi	72%	asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for …
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: asures are also imposed by health…

Eledon Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
COASTLANDS-CAPITAL-PARTNERS-LP	COASTLANDS-CAPITAL-PARTNERS-LP	80%	Coastlands Capital agreed to exchange 4,203,764 shares of the Company’s common stock for a pre-funded warrant to purchase an aggregate of 4,203,764 shares of common stock
ORANY	ORANY	72%	ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental appli…
SNYNF	Sanofi	72%	asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for …
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions…

Eledon Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ELDN-DEBT	Debt stack $555,000	90%	Market cache reports total debt of $555,000.
ELDN-DEBT-9264	Warrants outstanding: 0.001	90%	xbrl warrant detail from xbrl 2025-12-31.
ELDN-DEBT-9265	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2016-12-31.

Eledon Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Eledon Pharmaceuticals, Inc..

Eledon Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ELDN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 124 tracked holders.

Eledon Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
DBVTF	DBV TECHNOLOGIES	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
AZN	AstraZeneca PLC	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2

Eledon Pharmaceuticals, Inc. Supply Chain